Malaria prime/boost vaccines using adenoviral vectors and adjuvated proteins

摘要

Disclosed is the use of a replication-defective recombinant adenovirus comprising a heterologous nucleic acid encoding a CS antigen from a malaria-causing parasite, and an adjuvated proteinaceous antigen selected from a CS protein or an immunogenic fragment thereof comprising a C-terminal portion of the CS protein, four or more tandem repeats of the immunodominant region, and the surface antigen from hepatitis B virus, wherein said proteinaceous antigen is adjuvated with an adjuvant comprising QS21 and 3D-MPL in the manufacture of a medicament for the treatment or prevention of malaria, wherein said recombinant adenovirus is a simian, a canine, a bovine adenovirus or a human adenovirus serotype 11, 24, 26, 34, 35, 48, 49 or 50.